Search results
Results From The WOW.Com Content Network
Merck is forecasting 2024 revenue to climb by 5% to 7% over the 2023 result, while its earnings-per-share (EPS) target of $7.94 to $8.04 represent a midpoint increase of 7% from the company record ...
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
Science & Tech. Shopping. Sports
2014 – Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion). [16] [17] November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S. Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA. [18]
The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally. [6] [7]
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and ...